File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma

TitleHOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma
Authors
Issue Date1988
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1988, v. 22 n. 2, p. 169-171 How to Cite?
AbstractA total of 30 patients with recurrent or unresponsive diffuse, aggressive non-Hodgkin's lymphoma, who had previously received doxorubicin, cyclophosphamide, vincristine, and prednisone with or without bleomycin were treated with a combination of doxorubicin, vincristine, ara C, prednisone, and bleomycin (HOAP-Bleo). Complete remissions were achieved in 33.3% of the patients and partial remissions in 13.3%. Four of the ten complete responders relapsed at 4, 10, 11, and 18 months. Myelosuppression was the major toxicity and nonhematological toxicities were acceptable. Their median survival from the date of first relapse was only 4-5 months.
Persistent Identifierhttp://hdl.handle.net/10722/161749
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.date.accessioned2012-09-05T05:14:39Z-
dc.date.available2012-09-05T05:14:39Z-
dc.date.issued1988en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1988, v. 22 n. 2, p. 169-171en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161749-
dc.description.abstractA total of 30 patients with recurrent or unresponsive diffuse, aggressive non-Hodgkin's lymphoma, who had previously received doxorubicin, cyclophosphamide, vincristine, and prednisone with or without bleomycin were treated with a combination of doxorubicin, vincristine, ara C, prednisone, and bleomycin (HOAP-Bleo). Complete remissions were achieved in 33.3% of the patients and partial remissions in 13.3%. Four of the ten complete responders relapsed at 4, 10, 11, and 18 months. Myelosuppression was the major toxicity and nonhematological toxicities were acceptable. Their median survival from the date of first relapse was only 4-5 months.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleHOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2457455-
dc.identifier.scopuseid_2-s2.0-0023765013en_US
dc.identifier.volume22en_US
dc.identifier.issue2en_US
dc.identifier.spage169en_US
dc.identifier.epage171en_US
dc.identifier.isiWOS:A1988P610800013-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats